Searchable abstracts of presentations at key conferences in endocrinology

ea0084ps2-10-91 | Nodules & Cancer | ETA2022

Comparison of the clinicopathological features and oncologic outcomes of the classic papillary thyroid carcinoma with tall cell features and tall cell variant

Kim Kwangsoon

Background: The tall cell variant (TCV) of papillary thyroid carcinoma (PTC) (TCVPTC) is the most common aggressive variant of PTC. Classic PTC with tall cell features (TCF) is defined as PTC with noticeable tall cells but the percentage of these cells is lower than that required for the diagnosis of TCVPTC. We aimed to investigate the potential differences between TCVPTC and classic PTC with TCF with respect to clinicopathological characteristics and long-term oncologic outco...

ea0092ps2-13-03 | Surgery | ETA2023

Clinical application of pectoralis nerve block ii for flap dissection-related pain control after robotic transaxillary thyroidectomy: preliminary results of a randomized controlled trial

Kim Kwangsoon

Purpose: Few studies have examined the clinical utility of ultrasonography-guided pectoralis nerve block II (PECS II) during wide flap dissection of SP robot-assisted transaxillary thyroidectomy (SP-RATT). This study presents preliminary results of a randomized controlled trial.Methods: A total of 48 adult patients (aged ≥ 20 years) who underwent elective SP-RATT (including lobectomy) or total thyroidectomy from November 2022 to February 2023 at Se...

ea0101ps3-28-01 | Treatment – surgery | ETA2024

clinical impact of pectoral nerve ii block on postoperative pain, opioid usage, and patient recovery experience in robot-assisted transaxillary thyroidectomy: a prospective, randomized controlled trial

Kim Kwangsoon

Backgroud: Effective postoperative pain management with minimal opioid use is vital in robot-assisted transaxillary thyroidectomy (RATT), posing unique challenges in surgical flap-related pain control. Promising analgesic regional methods like the pectoral nerve II (PECS II) block are crucial for patients. To evaluate the efficacy of the PECS II block in reducing postoperative pain and opioid requirements and improving the quality of recovery in RATT.Met...

ea0092ps1-07-09 | Thyroid Cancer Diagnosis 1 | ETA2023

Clinical significance of tumor size in gross extrathyroidal extension to strap muscles(T3B) in papillary thyroid carcinoma

Park Joonseon , Kim Kwangsoon , Seong Bae Ja , Kim Jeongsoo

Background: It has been studied that larger tumor size in T3b has a worse prognosis than T3b with smaller tumor size. The present study aims to compare the clinicopathological characteristics among modified T categories and clarify the significance of tumor size in T3b on the DSS of differentiated thyroid carcinoma(DTC).Methods: A total of 6282 patients with DTC who underwent thyroid surgery at a single center were retrospectively analyzed. Patients with...

ea0101ps3-23-06 | Clinical thyroid cancer research-3 | ETA2024

Overweight as a risk factor for concomitant thyroid cancer in graves’ disease patients: a retrospective study

Park Joonseon , Seong Bae Ja , Kim Jeongsoo , Kim Kwangsoon

Background: Graves’ disease (GD) is an autoimmune disorder that causes hyperparathyroidism with the presence anti-TSH receptor antibodies (TR-Ab). The incidence of concomitant thyroid cancer in GD varies, and there is no clear consensus on the risk factors. Limited studies have examined the relationship between thyroid cancer in GD and obesity. The aim of the study was to identify the risk factors for concurrent thyroid cancer in GD patients and evaluate the impact of ove...

ea0084ps1-03-23 | Thyroid Cancer CLINICAL 1 | ETA2022

Comparison between minimal and gross ete for risk of recurrence in papillary thyroid carcinoma : a propensity score matching study

Park Joonseon , ku kang il , Kim Kwangsoon , Seong Bae Ja , kim jeongsoo

Background: The presence of extathyroidal extension (ETE) is associated with locoregional recurrence and distant metastases in papillary thyroid carcinoma (PTC). ETE is classified into gross ETE (gETE) and minimal ETE (mETE). The mETE was recently excluded from the T3 category in the TNM staging system. The purpose of this study is to compare the recurrence risk of mETE and gETE in PTC patients through propensity score matching analysis. And a comparison in the same way for pa...